NCT01836861View on ClinicalTrials.gov

IPI-145 ADME and Absolute Bioavailability Study

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

April 30, 2013

Study Completion Date

May 31, 2013

Conditions
Healthy
Interventions
DRUG

IPI-145

Intravenous infusion: approximately 2.8 μg IPI-145 containing 14.8 kBq of radioactivity; Oral suspension: 25 mg IPI-145 containing approximately 3.15 MBq of radioactivity; Oral capsule: 25 mg IPI-145

Trial Locations (1)

Unknown

Pharmaceuticals Research Association (PRA), Zuidlaren

All Listed Sponsors
lead

SecuraBio

INDUSTRY

NCT01836861 - IPI-145 ADME and Absolute Bioavailability Study | Biotech Hunter | Biotech Hunter